口服mizoprostol在资源贫困社区预防分娩后出血:一个随机对照试验
Richard J Derman1, Bhalchandra S Kodkany, Shivaprasad S Goudar
1University of Missouri-Kansas City School of Medicine, MO, USA.
Lancet (London, England)
|October 10, 2006
概括
在印度农村家庭分娩研究中,口服mizoprostol显著减少了产后出血. 这种可获得的药物是防止资源贫困环境中的孕产妇死亡率的可行选择.
科学领域:
- 产科和妇科 产科和妇科
- 全球健康 全球健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 产后出血 (PPH) 是全球主要的孕产妇死亡原因.
- 有效的PPH预防和治疗方法,如催产素,往往无法在资源贫困的环境中获得.
- 社区家庭分娩机构需要可行的PPH管理干预措施.
研究的目的:
- 评估口服mizoprostol在预防产后出血方面的疗效.
- 评估在资源有限的环境中作为催产素的潜在替代品的mizoprostol.
- 在社区家庭分娩环境中使用口服mizoprostol调查PPH率.
主要方法:
- 一个安慰剂受控试验,涉及印度农村的1620名妇女.
- 在分娩后随机选择接受口服美索普罗斯托尔或安慰剂.
- 主要结局:分娩后2小时内发生急性产后出血 (>或=500毫升出血) 的发生率.
主要成果:
- 口服mizoprostol显著降低了产后急性出血的发生率 (12.0%至6.4%,p<0.0001).
- 随着mizoprostol (262.3毫升至214.3毫升,p<0.0001) 的使用,平均产后血流量显著下降.
- 米索普罗斯托尔的使用与轻微的,短暂的副作用,如发寒和发烧有关.
结论:
- 口服mizoprostol有效降低产后出血率和血液损失.
- 该药物的低成本,稳定性和易于使用使其适用于资源贫困的环境.
- 米索普罗斯托尔在社区家庭分娩中为PPH预防提供了一个有希望的,安全的选择.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
